RxDoctor Payments Data

Michele Horne, MD

Internal Medicine · Monterey, CANPI 1972839363

Payments from drug & device makers

$2,825in general payments, 2019–2025

Across 81 payments — averaging $34.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$756
  • AbbVie$715
  • Lilly USA, LLC$451
  • Boehringer Ingelheim$226
  • Biohaven Pharmaceuticals, Inc.$213
  • Pfizer$145
  • plus $318 from 8 others

What the payments were for

  • Food & beverage$2,79399%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,825 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$95,279
Medicare patients
164
Services billed
662

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TopamaxTopiramate13$13,552
Levothyroxine Sodium120$1,879
Albuterol Sulfate HfaAlbuterol Sulfate37$1,719
Gabapentin117$1,555
SynthroidLevothyroxine Sodium12$1,098
Ezetimibe34$1,088
Sucralfate15$878
Rosuvastatin Calcium81$842
Nebivolol Hcl13$826
Montelukast Sodium59$743
Azelastine Hcl33$705
Omeprazole53$651
Atorvastatin Calcium65$562
Metoprolol Succinate28$558
Amlodipine Besylate110$515

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$715$1,09812 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$36$32017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Monterey

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →